Boston Scientific Corporation $BSX Shares Sold by Unisphere Establishment

Key Points

• Unisphere Establishment reduced its stake in Boston Scientific Corporation by 9.4%, now holding approximately $218.55 million worth of shares, which accounts for 1.9% of its investment portfolio.
• Boston Scientific reported a quarterly revenue of $5.06 billion, exceeding analyst estimates of $4.89 billion, with a 22.8% year-over-year increase in revenue.
• Several brokerages have raised their price targets for Boston Scientific, with a notable increase from $120.00 to $125.00 by Truist Financial, indicating a generally optimistic outlook for the company.

Unisphere Establishment trimmed its stake in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 9.4% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,166,400 shares of the medical equipment provider's stock after selling 225,000 shares during the quarter. Boston Scientific accounts for 1.9% of Unisphere Establishment's holdings, making the stock its 14th largest holding. Unisphere Establishment owned about 0.15% of Boston Scientific worth $218,546,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently bought and sold shares of BSX. GAMMA Investing LLC grew its stake in Boston Scientific by 11,720.3% during the 1st quarter. GAMMA Investing LLC now owns 2,577,887 shares of the medical equipment provider's stock worth $260,057,000 after purchasing an additional 2,556,078 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in Boston Scientific by 18.7% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 10,839,362 shares of the medical equipment provider's stock worth $968,172,000 after buying an additional 1,709,461 shares during the last quarter. Vanguard Group Inc. lifted its holdings in Boston Scientific by 1.3% during the 1st quarter. Vanguard Group Inc. now owns 134,588,729 shares of the medical equipment provider's stock worth $13,577,311,000 after buying an additional 1,697,945 shares during the last quarter. Price T Rowe Associates Inc. MD raised its position in shares of Boston Scientific by 18.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 10,610,487 shares of the medical equipment provider's stock worth $1,070,387,000 after acquiring an additional 1,664,108 shares in the last quarter. Finally, Assenagon Asset Management S.A. raised its position in shares of Boston Scientific by 161.9% during the 1st quarter. Assenagon Asset Management S.A. now owns 2,485,696 shares of the medical equipment provider's stock worth $250,757,000 after acquiring an additional 1,536,663 shares in the last quarter. 89.07% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. Raymond James Financial raised their target price on Boston Scientific from $121.00 to $124.00 and gave the stock a "strong-buy" rating in a research report on Thursday, July 24th. Morgan Stanley raised their target price on Boston Scientific from $120.00 to $125.00 and gave the stock an "overweight" rating in a research report on Friday, May 16th. Barclays raised their target price on Boston Scientific from $125.00 to $133.00 and gave the stock an "overweight" rating in a research report on Thursday, July 24th. Wells Fargo & Company raised their target price on Boston Scientific from $118.00 to $124.00 and gave the stock an "overweight" rating in a research report on Thursday, July 24th. Finally, Needham & Company LLC reissued a "buy" rating and set a $115.00 target price on shares of Boston Scientific in a research report on Wednesday, May 28th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $117.50.

Boston Scientific Stock Performance

Shares of Boston Scientific stock traded down $0.15 on Friday, hitting $107.14. The stock had a trading volume of 4,062,436 shares, compared to its average volume of 5,736,611. Boston Scientific Corporation has a 52-week low of $80.64 and a 52-week high of $108.94. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49. The stock has a market cap of $158.76 billion, a price-to-earnings ratio of 63.78, a P/E/G ratio of 2.58 and a beta of 0.65. The company's 50 day moving average price is $104.77 and its 200 day moving average price is $102.15.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.72 by $0.03. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The business had revenue of $5.06 billion during the quarter, compared to the consensus estimate of $4.89 billion. During the same period in the previous year, the business earned $0.62 EPS. The business's quarterly revenue was up 22.8% on a year-over-year basis. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, research analysts anticipate that Boston Scientific Corporation will post 2.85 EPS for the current year.

Insider Buying and Selling

In other Boston Scientific news, Director Edward J. Ludwig sold 4,000 shares of the company's stock in a transaction that occurred on Friday, July 25th. The stock was sold at an average price of $106.03, for a total transaction of $424,120.00. Following the completion of the sale, the director directly owned 18,479 shares of the company's stock, valued at $1,959,328.37. This represents a 17.79% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Yoshiaki Fujimori sold 2,901 shares of the business's stock in a transaction that occurred on Tuesday, July 29th. The shares were sold at an average price of $106.99, for a total value of $310,377.99. Following the completion of the transaction, the director directly owned 2,081 shares in the company, valued at approximately $222,646.19. The trade was a 58.23% decrease in their position. The disclosure for this sale can be found here. Insiders sold 174,214 shares of company stock valued at $18,397,457 in the last quarter. 0.50% of the stock is currently owned by insiders.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.